Results 51 to 60 of about 187,433 (291)

Identifying High‐Impact Solutions to Address Racial and Ethnic Health Disparities in Lupus: A Consensus‐Based Approach

Arthritis Care &Research, EarlyView.
Objective We conducted formative research aimed at identifying solutions that address inequitable health outcomes in lupus due to adverse social determinants of health (SDoH). Methods We conducted a search for keywords, which provided insights into potential solutions and initiatives underway. An advisory panel of lupus experts iteratively reviewed the
Joy Buie, Michael P. Fisher, Kristen Backor, Hannah Tyldsley, Ashira Blazer, Candace Feldman, Andrea Knight, S. Sam Lim, Barbara Ann Polk, Ed Yelin, Edith Williams, Karen H. Costenbader   +11 more
wiley   +1 more source

Knee Crepitus and Osteoarthritis Features in Young Adults Following Traumatic Knee Injury

Arthritis Care &Research, EarlyView.
Objective This study explored the association between knee crepitus and the presence, and worsening, of structural osteoarthritis features and self‐reported outcomes in young adults following traumatic knee injury. Methods One year following anterior cruciate ligament reconstruction (ACLR), 112 participants (41 female participants; median age 28 years ...
Jamon L. Couch, Brooke E. Patterson, Kay M. Crossley, Ali Guermazi, Matthew G. King, Danilo De Oliveira Silva, Jackie L. Whittaker, Michael A. Girdwood, Adam G. Culvenor   +8 more
wiley   +1 more source

Accelerator physics issues for the Very Large Hadron Collider [PDF]

, 1999
The goal of the Very Large Hadron Collider (VLHC) is to extend the energy frontier beyond LHC. The proposed design center of mass energy for the VLHC pp collider is 100 TeV, with a luminosity of 1*10/sup 34 / cm/sup -2/ sec/sup -1/ and an integrated ...
Jackson, A, Mishra, C S, Syphers, M J
core  

Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment

Arthritis Care &Research, EarlyView.
Objective Lupus nephritis (LN) management remains challenging, and novel noninvasive biomarkers are needed. This study quantified serum soluble mediators in the Accelerating Medicines Partnership (AMP) LN cohort to identify biomarkers of histologic features and treatment response.
Andrea Fava, Catriona A. Wagner, Carla J. Guthridge, Susan Macwana, Wade DeJager, Melissa E. Munroe, Peter Izmirly, H. Michael Belmont, Betty Diamond, Anne Davidson, Paul J. Utz, Michael H. Weisman, Philip M. Carlucci, Maria Dall'Era, Kenneth Kalunian, Chaim Putterman, Jennifer Anolik, Jennifer L. Barnas, David Wofsy, Diane Kamen, Richard A. Furie, Deepak A. Rao, the Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Chun‐Hao Lee, Derek Fine, Manny Monroy‐Trujillo, Ummara Shah, Mariko Ishimori, Robert M. Clancy, Michael Belmont, Ming Wu, Nicole Bornkamp, Evan Der, Beatrice Goilav, Nicole Jordan, Daniel Schwartz, James Pullman, David Wofsy, Dawn Smilek, Patti Tosta, Matthias Kretzler, Celine C. Berthier, E. Steve Woodle, Dave Hildeman, Michael Brenner, Michelle Petri, Joel M. Guthridge, Jill Buyon, Judith A. James   +48 more
wiley   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

Arthritis Care &Research, EarlyView.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung, John P. Shelley, Gul Karakoc, John Still, Xiaodi Ruan, Jonathan Mosley, C. Michael Stein, Vivian K. Kawai   +7 more
wiley   +1 more source

Tevatron accelerator physics and operation highlights

, 2011
The performance of the Tevatron collider demonstrated continuous growth over the course of Run II, with the peak luminosity reaching 4\times1032 cm-2 s-1, and the weekly integration rate exceeding 70 pb-1.
Valishev, A.
core   +1 more source

The temporal trends and short‐ and long‐term mortality of people with acute myocardial infarction and rheumatoid arthritis: a nationwide cohort study

Arthritis Care &Research, Accepted Article.
Aims We investigated whether a diagnosis of rheumatoid arthritis (RA) affects the quality of inpatient acute myocardial infarction (AMI) care and long‐term mortality post‐AMI. Methods We analysed data from 784,091 adults, 6,047 with a diagnosis of RA, from England and Wales hospitalised with AMI between 2005 and 2019 from the MINAP registry, linked ...
Megan Butler, Nicholas Weight, Muhammad Rashid, Rodrigo Bagur, Purvi Parwani, Samantha Hider, Edward Roddy, Robert Butler, Mamas A Mamas   +8 more
wiley   +1 more source

Associations of Sleep and Shift Work with Osteoarthritis Risk

Arthritis Care &Research, Accepted Article.
Objective Daily rhythms may be critical for maintaining homeostasis of joint tissues. We aimed to investigate the relationships between circadian clock disruption, sleep, and osteoarthritis (OA) risk in humans. Methods In the UK Biobank, a prospective 500,000‐person cohort, we evaluated associations between sleep duration, sleeplessness/insomnia, and ...
Elizabeth L. Yanik, Abigail Bridgeman, Erik D. Herzog, Vy Pham, Bradley A. Evanoff, Farshid Guilak   +5 more
wiley   +1 more source

A Large Hadron Electron Collider at CERN

, 2012
This document provides a brief overview of the recently published report on the design of the Large Hadron Electron Collider (LHeC), which comprises its physics programme, accelerator physics, technology and main detector concepts.
Adolphsen, C., Adzic, P., Akay, A. N., Aksakal, H., Albacete, J. L., Alekhin, S., Allanach, B., Allport, P., Andreev, V., Appleby, R. B., Arikan, E., Armesto, N., Azuelos, G., Bai, M., Barber, D., Bartels, J., Behnke, O., Behr, J., Belyaev, A. S., Ben-Zvi, I., Bernard, N., Bertolucci, S., Bettoni, S., Biswal, S., Blümlein, J., Bogacz, A., Bracco, C., Bracinik, J., Brandt, G., Braun, H., Brodsky, S., Brüning, O., Bulyak, E., Buniatyan, A., Burkhardt, H., Böttcher, H., Cakir, I. T., Cakir, O., Calaga, R., Caldwell, A., Cetinkaya, V., Chekelian, V., Ciapala, E., Ciftci, A. K., Ciftci, R., Cole, B. A., Collins, J. C., d'Enterria, D., D'Onofrio, M., Dadoun, O., Dainton, J., DiNezza, P., Dudarev, A., Eide, A., Enberg, R., Eroglu, E., Eskola, K. J., Favart, L., Fernandez, J. L. Abelleira, Fitterer, M., Forte, S., Gaddi, A., Gambino, P., García, R. Tomás, Gehrmann, T., Gladkikh, P., Glasman, C., Glazov, A., Godbole, R., Goddard, B., Greenshaw, T., Guffanti, A., Guzey, V., Gwenlan, C., Han, T., Hao, Y., Haug, F., Herr, W., Hervé, A., Holzer, B. J., Ishitsuka, M., Jacquet, M., Jeanneret, B., Jensen, E., Jimenez, J. M., Jowett, J. M., Jung, H., Karadeniz, H., Kate, H. Ten., Kayran, D., Kilic, A., Kimura, K., Klees, R., Klein, M., Klein, U., Kluge, T., Kocak, F., Korostelev, M., Kosmicki, A., Kostka, P., Kowalski, H., Kraemer, M., Kramer, G., Kuchler, D., Kuze, M., Lappi, T., Laycock, P., Levichev, E., Levonian, S., Litvinenko, V. N., Lombardi, A., Maeda, J., Marquet, C., Mellado, B., Mess, K. H., Milanese, A., Milhano, J. G., Moch, S., Morales, H. García, Morozov, I. I., Muttoni, Y., Myers, S., Nandi, S., Nergiz, Z., Newman, P. R., Omori, T., Osborne, J., Paoloni, E., Papaphilippou, Y., Pascaud, C., Paukkunen, H., Perez, E., Pieloni, T., Pilicer, E., Pire, B., Placakyte, R., Polini, A., Ptitsyn, V., Pupkov, Y., Radescu, V., Raychaudhuri, S., Rinolfi, L., Rizvi, E., Roeck, A. De., Rohini, R., Rojo, J., Russenschuck, S., Sahin, M., Salgado, C. A., Sampei, K., Sassot, R., Sauvan, E., Schaefer, M., Schneekloth, U., Schulte, D., Schörner-Sadenius, T., Senol, A., Seryi, A., Sievers, P., Skrinsky, A. N., Smith, W., South, D., Spiesberger, H., Stasto, A. M., Strikman, M., Sullivan, M., Sultansoy, S., Sun, Y. P., Surrow, B., Szymanowski, L., Taels, P., Tapan, I., Tasci, T., Tassi, E., Terron, J., Thiesen, H., Thompson, L., Thompson, P., Tokushuku, K., Tommasini, D., Trbojevic, D., Trinh, T. N., Tsoupas, N., Tuckmantel, J., Turkoz, S., Tywoniuk, K., Ullrich, T., Unel, G., Urakawa, J., VanMechelen, P., Variola, A., Veness, R., Vivoli, A., Vobly, P., Wagner, J., Wallny, R., Wallon, S., Watt, G., Weiss, C., Wiedemann, U. A., Wienands, U., Willeke, F., Xiao, B. -W., Yakimenko, V., Zarnecki, A. F., Zhang, Z., Zimmermann, F., Zlebcik, R., Zomer, F.   +208 more
core  

Use of a Molecular Signature Response Classifier to Inform Treatment Selection Improves Clinical Disease Activity Among Patients with Rheumatoid Arthritis Initiating a Biologic or Targeted Synthetic Disease‐modifying Antirheumatic Drug

Arthritis Care &Research, Accepted Article.
Objective We assessed the effectiveness of PrismRA to improve clinical outcomes among patients with rheumatoid arthritis (RA) initiating treatment with a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) Methods PrismRA incorporated 19 gene expression features and 4 clinical features to assess a patient's likelihood of ...
Fenglong Xie, Timothy Beukelman, Nicholas P McCormick, Jeffrey R Curtis   +3 more
wiley   +1 more source